Sellas Life Sciences Shares Slipped Overnight
The company stock declined 1% as investors look ahead to upcoming research presentations.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Is now a good time for individual investors to base trades on speculative pharmaceutical clinical trials?
Shares of Sellas Life Sciences fell 1% overnight, contributing to a 14% decline over the past month. The company is currently preparing to present three preclinical studies regarding SLS009 at an upcoming pancreatic cancer conference.
Why it matters
Retail traders are seeking clarity on the potential expansion of SLS009 testing into pancreatic cancer patient populations. The ongoing performance of the company's stock remains a focus for investors tracking the development of its drug pipeline.
Sellas has enrolled 28 of 80 planned patients for its Phase 2 AML study, while the Regal study has recorded 78 of 80 prespecified events. Despite a 14% monthly dip, the stock maintains a 206% increase year-to-date.
The players
Sellas Life Sciences
This is a biopharmaceutical company focused on the development of novel cancer immunotherapies.
University of Wisconsin-Madison
This is a public research university that collaborates with industry partners on clinical and preclinical health studies.
The details
Sellas Life Sciences is collaborating with researchers from the University of Wisconsin-Madison to highlight new data on pancreatic cancer models. The firm plans to finalize its current study data by locking the database and unblinding findings once the remaining two events are recorded.
Timeline
August 2026: The company reported the status of patient enrollment for its AML study.
September 24, 2026: Sellas Life Sciences stock slipped 1% overnight.
September 25-28, 2026: The AACR Conference on Pancreatic Cancer will be held in San Diego.
Q4 2026: Sellas expects to release topline results for its AML study.
The Big Picture
The progress of the Regal study serves as a primary benchmark for the company’s clinical development timeline. Investors monitor these study milestones to gauge when the company will move toward potential regulatory filings.
The ongoing testing of SLS009 in AML and pancreatic cancer models remains strictly in the clinical and preclinical research phases. Patients and families should note that these treatments are not yet available for general clinical use.
The takeaway
Investors should remain focused on the company's ability to reach the 80-event milestone for the Regal study as a indicator of future progress. Watching the upcoming conference presentations may provide better insight into the potential efficacy of the drug in new cancer models.
What happens next
Sellas is scheduled to participate in the AACR Conference on Pancreatic Cancer from September 25 to 28, 2026, and expects to release topline results for its AML study in the fourth quarter of 2026.
Further reading
For more information on the latest clinical developments, visit the Cancer section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time for individual investors to base trades on speculative pharmaceutical clinical trials?
